Marking its in-person return after three years, the 31st PDA/FDA Joint Regulatory Conference in Washington D.C. opened with perspective from FDA on COVID-19 challenges, key learnings, and best practices coming out of the pandemic. To illustrate progress, many products that moved forward through emergency use authorizations (EUAs) are now maturing into full drug applications including biologics license applications (BLAs).
